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Abstract 
 
 
 
 
 
 
 
 
 
his study aimed to add some new insight into the 
epidemiology, aetiology and surgical treatment of Breast 
Cancer-Related Lymphedema (BCRL). Results demonstrate 
that about 45% of women will develop BCRL after 3 years from breast 
cancer treatment. Obese women in advanced breast cancer stages, 
treated with mastectomy and extensive axillary lymphadenectomy (total 
number of removed lymph nodes ≥ 20) are at major risk to develop 
BCRL, thus they should be referred to monitoring programs with the 
aim to prevent the onset of lymphedema. However, once developed, 
lymphedema can be treated with customized surgical procedures that 
allow improvement in the quality of life of selected BCRL patients. 
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Summary 
 
 
  
 
 
 
 
 
 
urpose: Breast Cancer-Related Lymphedema (BCRL) is a 
challenging psychophysical disease affecting women after 
breast cancer treatment. A lack of standardized diagnostic 
and surgical strategies contribute to the large variations available in 
literature about the prevalence and identification of risk factors for 
BCRL as well as on outcomes of its surgical treatment. The aims of this 
study were: to estimate the long-term prevalence of BCRL by using a 
standardized diagnostic protocol; to determine risk factors associated 
to BCRL development; to report the outcomes of a tailored surgical 
protocol adopted in selected BCRL patients. 
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Materials and Methods: the study was divided into two phases. Phase 
I (cross sectional study) was designed to evaluate the prevalence and 
risk factors of upper-limb lymphedema in a cohort of breast cancer 
survivors 3 years after unilateral mastectomy or breast-conservative 
surgery with axillary lymph node dissection. A questionnaire was 
administered to each patient to assess demographic, lifestyle, clinical 
and pathological factors associated with BCRL. Presence of 
lymphedema was determined by using a combination of three 
diagnostic modalities: circumferential tape measurement, self-reported 
lymphedema symptoms and lymphoscintigraphy. Lymphedema patients 
were classified for staging and severity according to the International 
Society of Lymphology system classification. Univariate and 
multivariate statistical analyses were used to evaluate risk factors for 
lymphedema.  
Phase II (prospective study) was conducted to evaluate the 
effectiveness of a surgical protocol applied for the treatment of selected 
BCRL patients recruited from phase I. Preoperatively, each patient 
underwent physical examination and Indocyanine Green (ICG) 
lymphography in order to evaluate the presentation of lymphedema 
(pitting or no-pitting edema) and the functionality of the lymphatic 
vessels. Patients with active lymphatic channels were candidates for 
linfatico-venular anastomosis (LVA). Patients with non-functioning 
lymphatic channels and non-pitting lymphedema were candidates for 
circumferential liposuction (CL). Postoperatively each patient 
underwent upper limbs circumferential measurements at 1, 3, 6 and 12 
months after surgery. Post-treatment measurements were compared to 
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the preoperative circumference values to evaluate limb volume 
reduction. 
Results: in Phase I, a total of 80 breast cancer survivors were enrolled. 
The overall prevalence of lymphedema was 45% (CI 95% 0.3385; 
0.5653). The univariate analysis showed significant association 
between lymphedema and BMI ≥ 30 Kg/m2 (OR = 2.96, p = 0.035), 
mastectomy (OR = 4.32, p = 0.021), number of excised lymph nodes ≥ 
20 (OR= 2.96, p = 0.035) and advanced TNM stages of breast cancer 
(OR = 2.63, p = 0.042). Smoke was found to be a protective factor for 
development of lymphedema  (OR = 0.18, p = 0.031). At the 
multivariate analysis only a number of excised lymph nodes ≥ 20  (OR 
= 1.09, p = 0.044 ) and mastectomy (OR = 3.93, p = 0.047) remained 
significantly associated to the occurrence of lymphedema. 
In phase II, six patients were selected. Three showed early II stage 
lymphedema with pitting edema and active lymphatic channels, thus 
they underwent lymphatico-venular anastomosis (LVA group). The 
remaining three patients with late II stage lymphedema, no pitting 
edema and non-functioning lymphatic vessels underwent 
circumferential liposuction (CL group). At 12 months follow-up, upper 
limbs circumferential measurements demonstrated an average 
reduction of limb volume excess of 53.3% and 88.7% in LVA and CL 
groups respectively. 
Conclusions: 
The current study demonstrate that the standardization of diagnostic 
and surgical protocols employed in the management of Breast Cancer-
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Related Lymphedema allows to define accurately the entity of the 
disease, the classes of patients considered at major risk and those who 
would benefit from surgical treatment. 
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CHAPTER 1 
 
 
 
Introduction 
 
 
 
 
 
 
 
reast Cancer-Related Lymphedema (BCRL) is defined as a 
chronic swelling syndrome due to obstruction or disruption 
of the lymphatic drainage system in patients following 
breast cancer surgical treatment.1 
It represents a challenging psychophysical disease associated 
with different symptoms such as heaviness, stiffness, discomfort, 
paraesthesia and pain. In patients with long-standing untreated 
lymphedema, infections are the most common complications and in 
rare cases a lymphangiosarcoma may develop.2 
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Currently, little is known about risk factors and the real 
prevalence of BCRL. In addition, different surgical treatments are 
described in the literature ranging from functional therapeutic 
techniques to palliative solutions. However, despite large series are 
available and these procedures are becoming more popular, there is 
still a huge variability in reported outcomes.3-6  
This inconsistency in the data can be attributed to the lack of 
standardization of modalities employed for the assessment of risk 
factors and diagnosis of BCRL, and to the variability in the indications 
and outcome measures used in the surgical treatment of the disease.  
The main objectives of this study were: to estimate the 
prevalence and risk factors for lymphedema in a cohort of breast 
cancer survivors by using a standardized protocol; to report our 
preliminary experience and outcomes with the use of lymphatico-
venular anastomoses and circumferential liposuction in the surgical 
treatment of selected breast cancer-related lymphedema patients. 
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CHAPTER 2 
 
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
his study was approved by local Ethics Committee 
(N°8/2016) and was performed  in  accordance  with  the  
ethical guidelines  of  the  Declaration  of  Helsinki. It was 
divided into two phases. 
2.1. Phase I: cross-sectional study  
In this phase, the study was designed to determine the 
prevalence and risk factors for upper-limb lymphedema in a cohort of 
breast cancer survivors 3 years after unilateral mastectomy or breast-
conservative surgery (lumpectomy/quadrantectomy) with axillary lymph 
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node dissection (ALND) for clinically or histologically [after sentinel 
lymph node biopsy (SLNB)] node-positive breast cancer. 
Sample size of this study was determined a priori to be about 80 
patients using the Open Source Epidemiologic Statistics for Public 
Health (OpenEpi, version 3.01). Sample size calculation was based on 
an estimated prevalence of the outcome factor in the population 
(lymphedema) of 21,4%, according to previous studies.7 Two sided 
significance level (alpha error) was set at 5% and desired precision of 
the estimate was set at  9%.  
The study started on June 1, 2013 and concluded on December 
31, 2015, date on which all patients were examined at a distance of 3 
years after surgery. 
2.1.1. Patients’ recruitment 
Initially, n=220 women that underwent breast cancer surgery 
and ALND performed by the same surgeon in the period between 
January 1, 2010, and December 31, 2012 were considered consulting 
the registry of the Department of Oncology of the University Hospital “P. 
Giaccone” of Palermo, Italy. A trained research assistant performed a 
pre-screening of the sample by analysis of medical records to select 
women who met the following inclusion criteria: age ranged between 18 
and 85 years on the date of surgery, unilateral breast cancer diagnosis, 
unilateral breast and axillary surgical treatment, no history of primary 
lymphedema. A unilateral diagnosis and treatment allowed using the 
contralateral limb as a control for lymphedema. Among these patients, 
n=1 was excluded because of a history of bilateral breast cancer 
surgical treatment. All eligible women (n=219) were contacted by 
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telephone to participate in the study. Of these, n=8 died due to non-
cancer causes, n=51 were not contactable and n= 80 refused to 
participate. Finally, 80 women were enrolled and gave informed, written 
consent prior to participation. Figure 1 shows patients’ recruitment flow 
chart. 
2.1.2. Data collection and risk factors assessment  
Each patient was interviewed by the same research staff 
member. A questionnaire was administered to assess potential risk 
factors for development of lymphedema. The following data were 
recorded:  
• demographic, clinical and lifestyle characteristics of 
patients at time of breast and/or axillary surgery [age, 
body mass index (BMI), side of dominance/handedness, 
history of tobacco, alcohol and caffeine use]; 
• past medical history (comorbidities such as diabetes, 
hypertension, chronic heart failure, renal failure, thyroid 
disease, familiarity for lymphedema and history of 
infection, musculoskeletal or osteo-articular disorders, 
venous incompetence, surgery or trauma in both upper 
limbs);  
• tumour characteristics (histological type, disease stage 
by using AJCC TNM staging);8 
• characteristics of breast surgery {treated side, type of 
surgery [breast conservative surgery 
(lumpectomy/quadrantectomy) or mastectomy]}; 
• characteristics of axillary surgery (treated side, number of 
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removed lymph nodes, number of metastatic lymph 
nodes); 
• types of breast cancer adjuvant therapies (radiotherapy, 
chemotherapy, hormonotherapy, immunotherapy). 
2.1.3. Lymphedema assessment 
Determination of lymphedema was based on objective 
(circumference measurements) and subjective (patient perception of 
lymphedema) assessment clinical methods in combination with 
instrumental investigation (lymphoscintigraphy).  
Specifically, each patient underwent circumference 
measurement of upper limbs. In the absence of a baseline 
measurement, the upper limb ipsilateral to axillary lymphadenectomy 
was defined as “treated side” and the contralateral limb was defined as 
“untreated side” and used as control assuming that it was functionally 
intact. Patients were asked to sit with the arms supported on a table. 
Measurements were taken keeping both upper limbs in a similar 
position with 90° elbow flexion and hand palm up. On the volar aspect 
of the limbs, an imaginary line joining the apex of the third finger of 
each limb (point 0) with the acromioclavicular joint was drawn. Several 
points placed at 10 cm intervals from the point 0 up to the armpit were 
marked along the drawn line using a skin-marker pencil. 
Circumferences on treated and untreated limb were measured and 
compared at each marked point, placing the top edge of a flexible, non-
stretching measuring tape just below the mark. Measurements were 
photographed and recorded on a database (Figure 2). Difference 
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between two-limb circumferences (L) at any level of more than 2 cm 
was considered as clinical sign of lymphedema.9-10 
Indirect volume for each limb was calculated on the basis of the 
measurements using a truncated cone volume (Vtc) formula for the 
forearm and the arm, as follows: !"# = !!!ℎ  (!! + !! + !") =    (!!!!!!!")  !!"# ; and a cylinder volume (Vc) 
formula for the hand, as follows: !" = !!!ℎ = !!!!! . R and r are radius of 
two consecutive circumference measurements, C and c are 
circumferences of two consecutive measurements and h is height. 
Giving a fixed value to the height (10 cm), the total Limb Volume (LV) 
was calculated as follows:  !"!"! +!!! + !!!!!!!!!!! + !!!!!! +!"!! !!! (Figure 
3). This method demonstrated excellent inter- and intra-observer 
reproducibility in comparison to water displacement which is 
considered the gold standard.11-13 
Then, patients were asked if they noted the presence of 
heaviness and/or swelling on the treated limb. These two subjective 
symptoms are reported to be highly predictive of lymphedema and 
were used in this study to proceed to the instrumental investigation.14-16 
Patients that experienced swelling or heaviness and did not 
show clinical features of lymphedema at the circumference 
measurements, were invited to underwent lymphoscintigraphy to 
recognise subclinical forms of lymphedema. All lymphoscintigraphies 
were performed according to the following protocol: with the patient in 
the supine position and the upper limbs positioned alongside the body, 
1mCi (37 MBq) of 99 mTc-labeled nanocolloidal albumin (Nanocoll, Ge 
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Healthcare Srl, Milan, Italy) in a volume of 0.2 ml was simultaneously 
injected intradermally in the second web space of both hands, by two 
experienced nuclear radiologists. Resistance to injection, blanching 
and a visible raised bleb confirmed the intradermal location. Images 
were acquired on a dual-head gamma camera equipped with ultra high-
resolution low energy collimators and recorded with a 10% energy 
window centered on a 140-kV photopeak of 99mTc. Anterior and 
posterior partial whole body images (128x128 matrix) were taken at 
rest from the injection site to the axilla starting at 2 time points, 20 and 
60 minutes after the injection. Thereafter, patients were asked to 
squeeze a soft ball simultaneously with both hands for 20 minutes and 
then imaging was repeated at 120 minutes. Absent visualization of 
supraclavicular or infraclavicular lymph nodes and/or presence of 
dermal backflow were considered lymphoscintigraphic signs of 
lymphedema (Figure 4).17-19 
After clinical and instrumental evaluation, patients were 
categorized into two groups according to the presence (cases) or 
absence (non-cases) of unilateral lymphedema. Figure 5 shows the 
diagnostic algorithm used in this study. 
Lymphedema patients (cases) were classified using the staging 
and severity system of the International Society of Lymphology (ISL). 
The staging system is based on details about the amount of swelling 
and the condition of the skin and tissues at each stage. Currently the 
ISL lymphedema staging system consists of four levels being 
numbered from 0 to III (Table 1). Stage 0 lymphedema refers to a latent 
or sub-clinical condition where swelling is not yet evident despite 
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impaired lymph transport. Patients may report a feeling of heaviness in 
the limb, but many patients are asymptomatic in this latency stage. It 
may exist months or years before overt oedema occurs. Stage I 
lymphedema is referred to as “reversible lymphedema”. In this stage, 
the patient presents with very soft, pitting edema with no fibrosis due to 
an early accumulation of fluid relatively high in protein content. 
Prolonged elevation of the limb leads to complete resolution of the 
clinically evident swelling. Stage II lymphedema, also called 
“spontaneously irreversible lymphedema,” presents with intradermal 
fibrosis that decreases tissue suppleness and reduces the ability of the 
skin to indent (“pit”) with pressure. Applying firm pressure into the 
tissue for at least 5 seconds assesses pitting edema. If an indentation 
remains after the pressure is released, pitting edema is present. In this 
stage resolution of clinically evident lymphedema is rarely possible with 
elevation. Late in Stage II, the limb may or may not pit as excess fat 
and fibrosis supervenes. Stage III is also called “lymphostatic 
elephantiasis”. It is associated with a significant increase in the severity 
of the fibrotic response, tissue volume, and other skin changes such as 
papillomas, cysts, fistulas, and hyperkeratosis. Skin folds on the wrists 
and ankles deepen, the patient may present with slight or no pitting 
edema. Within each stage, severity of lymphedema based upon 
volume differences between the lymphedematous limb and the 
contralateral normal limb was defined as mild (<20 percent increase), 
moderate (20 to 40 percent increase), or severe (>40 percent 
increase) (Table 2) .14,20 
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2.1.4. Statistical Analysis 
Statistical analysis was conducted using the statistical software 
R (R version 3.1.2). Descriptive statistics (mean ± SD; range, 
frequency and percentage) were calculated for subject characteristics. 
Considering the presence of lymphedema as outcome of interest, 
population was divided into two groups: cases (lymphedema patients) 
and non-cases (no lymphedema patients). The marginal effect of each 
variable on lymphedema occurrence was studied through univariate 
analysis. The association between discrete/categorical variables and 
lymphedema occurrence was studied through Odds Ratios. Fisher 
Exact Test was used to evaluate any statistically significant difference 
in the two groups. The association between continuous variables and 
lymphedema occurrence was studied through mean differences. 
Welch-Satterthwaite T-Test was used to evaluate any statistically 
significant difference in the two groups. Therefore, a multivariate 
analysis was conducted. A logistic regression model was used to 
examine the correlation between statistically significant variables and 
the outcome of interest (lymphedema occurrence).  
Age and BMI were examined respectively at a cut-point of 60 
years and 30 Kg/m2 because it is expected that lymphatic function 
should be altered over these values.17,21-24 
Breast cancer stages III and IV were considered advanced 
according to the AJCC TNM staging system.8, 25-27 
Number of excised and positive (for metastasis) lymph nodes 
were examined as continuous variables and at a cut-point of 20 and 4 
lymph nodes respectively.28-29 Significance was set at P 0.05. 
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2.2. Phase II: prospective study  
In the second phase, the study was designed to evaluate the 
effectiveness of surgical treatment of lymphedema.  
Lymphedema patients recruited from phase I who met the 
following inclusion criteria were invited to undergo lymphedema 
surgical treatment: a) age ranged between 18 and 70 years, b) no 
breast cancer residual disease or recurrence; c) ASA ≤3; d) past history 
of lymphedema conservative therapy (at least 6 months) with poor 
results. Exclusion criteria were: a) ongoing chemo/radiotherapy; b) 
venous insufficiency and thrombosis in the affected limb.  
Patients who accepted to participate gave informed, written 
consent prior undergoing the surgical protocol described below. 
2.2.1. Preoperative assessment 
Each patient underwent physical examination and Indocyanine 
Green (ICG) lymphography in order to determine an appropriate 
surgical therapeutic strategy.  
Physical examination was performed to differentiate between 
pitting and non-pitting edema. Pitting edema is characterized by lymph 
fluid collection in the adipose tissue and is mainly recognized in the 
early stages of lymphedema (stage I to early II). Non-pitting edema 
argues for an advanced stage of the disorder (late stage II to III), 
characterized by severe fibrosis and hypertrophy of adipose tissue.14,30 
ICG lymphography was conducted to assess the functionality of 
the lymphatic vessels. ICG is a water-soluble fluorescent dye that has 
been used mainly to map blood flow in the heart, liver and eye when 
administered intravenously. In assessment of the lymphatic system, 
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ICG is injected subcutaneously where it binds to albumin and is taken 
up by the lymphatic system where it can be detected using near infra-
red range camera system deep in the tissue.31-38 
In this study, ICG lymphography was performed as follows. With 
the patient in supine position, 0,2 ml of ICG (Indocyanine Green 
Pulsion, PULSION Medical System AG, Munich, Germany) was 
injected subcutaneously in the second web space of the affected limb. 
Immediately after ICG injection, an infrared camera system 
[Photodynamic Eye (PDE); Hamamatsu Photonics K.K., Hamamatsu, 
Japan], composed of a camera unit, near-infrared–emitting diodes, and 
a controller unit that operates the camera, was used in order to 
illuminate with near infrared light the skin of the affected limb and to 
image the fluorescence emitted by ICG absorbed in subcutaneous 
lymph vessels. Functional and active lymphatic vessels were visualized 
on a display as fluorescent channels.  
Patients with active lymphatic channels were considered 
candidates for linfatico-venular anastomosis (LVA). In cases of non-
functioning lymphatic channels and non-pitting lymphedema, patients 
were candidates for circumferential liposuction (CL). Patients with non-
functioning lymphatic channels and pitting lymphedema, were invited to 
perform intensive physical rehabilitation therapy and then they were 
revaluated for the possibility to undergo circumferential liposuction.30 
2.2.2. Lymphatico-venular anastomosis technique 
LVA is a derivative surgical procedure. The main objective is to 
redirect the lymph to the venous system directly, without going through 
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the thoracic duct. This procedure can be performed only in presence of 
functioning lymph vessels.30 
In this study the procedure was performed as follows. 
Preoperatively, 0,2 ml of ICG were injected in the second web-space of 
the affected hand. PDE system confirmed that ICG was flowing up 
through the lymphatic vessels in the adipose tissue. Then the location 
and paths of active lymphatic channels were traced on the skin using a 
marker pencil. 
Under general anaesthesia, after disinfection of the affected 
limb, an incision of about 2 cm in length was made over the proximal 
side of the fluorescent active lymphatic vessels. After skin incision, 
venules (with a diameter of 0.5 to 1 mm) that lie beneath the dermis or 
in the superficial fat layer and adjacent lymphatic vessel (with a 
diameter of 0.5 to 1 mm) were exposed and separated by using an 
operative microscope. Once isolated, lymphatic vessel and adjacent 
venule were transected and, depending on the vessels diameter, an 
end-to-end (distal stump of the lymphatic vessel with proximal stump of 
the venule) or end-to-side anastomosis was performed with four to 
eight interrupted stitches using nylon 10/0 or 11 /0. Number of 
anastomoses depended on the number of active lymphatic vessels 
visualized by using ICG lymphography. Finally, patency of anastomosis 
was tested by injecting 0,2 ml of Patent Blue 2 cm distal the skin 
incision. Lymph fluid was seen flowing through the anastomosis along 
the vein. Skin incision/s was/were closed with interrupted stitches using 
nylon 4/0 (Figure 6).  
	   	   	   22	  
	  
In the immediate postoperative period (the first 48 hours) patient 
was invited to elevate the affected limb. On postoperative day 3, patient 
started muscular activation by squeezing a rubber ball. At day 21, 
patient was invited to begin physical activity (swimming). Compression 
garments were not prescribed. 
2.2.3. Circumferential liposuction technique 
Circumferential liposuction is an ablative surgical procedure. 
The main objective is to reduce the volume of the affected limb by 
removing the hypertrophied adipose tissue. This technique can be 
performed only in absence of functioning lymph vessels as it destroys 
the remaining lymphatic channels. Of note, it should be reserved only 
for compliant patients who are committed to wearing lifelong 
compression garments.30,39 
In this study, the procedure was performed according to the 
technique described by Brorson.39 Specifically, Made-to-measure 
compression garments (two sleeves with gauntlets) were measured 
and ordered 2 weeks before surgery, using the healthy upper limb as a 
template. Under general anaesthesia, a tourniquet was placed at the 
proximal part of the affected limb. Ten to fifteen, 3-mm-long incisions  
were made circumferentially on the entire affected limb until the 
tourniquet and a tumescent saline solution (1 to 2 L) containing low-
dose adrenaline and lignocaine was injected in the adipose tissue to 
reduce blood loss. Tourniquet was inflated and power-assisted 
liposuction was performed circumferentially from the wrist to the 
shoulder using 15 and 25 cm long cannulas with diameter of 3 and 4 
mm. After this phase a variation in the technique described by Brorson 
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was introduced. Specifically, when the arm distal to the tourniquet was 
treated, a multilayer bandage (deep layer: sterile gauze pads; middle 
layer: absorbent batting bandage fibre bonded; superficial layer: elastic 
bandage) instead of sterilized made-to-measure compression sleeve 
and glove was applied in order to absorb bleeding and reduce edema. 
The tourniquet was removed and the most proximal part of the upper 
limb was treated using the tumescent technique. Finally, the multilayer 
bandage was continued proximally to cover the shoulder. The incisions 
were left open to drain in to the multilayer bandage (Figure 7). An 
isoxazolyl penicillin was given intravenously for the first 24 hours and 
then in tablet form until incisions were healed (10 to 14 days after 
surgery).  
On postoperative day 2, the multilayer bandage was removed 
and the first set of garments was applied. On postoperative day 3, the 
first set was removed and replaced with the second set while the first 
was washed and dried. This routine was repeated every 2 days for two 
weeks. After the 2-week control, the garments were changed every 
day.  
2.2.4. Postoperative assessment 
Upper limbs circumferential measurements were performed at 1, 
3, 6 and 12 months postoperatively. Post-treatment measurements 
were photographed, recorded on a database and compared to the 
preoperative circumference values to evaluate the effectiveness of the 
surgical treatment.  
 
 
	   	   	   24	  
	  
CHAPTER 3 
 
 
 
Results 
 
 
 
 
 
 
 
 
 
3.1. Phase I: cross sectional study  
Eighty right-handed breast cancer women with age ranging 
between 37 and 83 years (mean ± SD: 58.16 ± 9.63 yr) and body mass 
index (BMI) ranging from 18.3 to 46.6 kg/m2 (mean ± SD: 28.1 ± 5.84 
kg/m2) were studied. Of these, 33.75% and 88.75% reported alcohol 
and coffee consumption respectively, 16.25% were current smokers, 
81.25% had co-morbidities, 11.5% had a past history of upper limb 
trauma. Only 1 patient had familiarity for lymphedema. Demographical 
and anamnestic characteristics of examined patients are shown in 
Table 3. 
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Primary breast cancer was located on the right breast in 57.50% 
(46/80) of patients and on the left breast in 42.50% (34/80). 86.25% 
(69/80) of patients had a ductal carcinoma and 13.75% (11/80) had a 
lobular carcinoma. Mastectomy was performed in 18.75% (15/80) of 
patients and breast conserving surgery (BCS) in the remaining 81.25% 
(65/80). Axillary lymphadenectomy was performed in all cases. The 
average number of excised lymph nodes and positive lymph nodes 
were 17.27 (SD: ± 6.13) and 4 (SD: ± 5.41) respectively. Adjuvant 
chemotherapy was given in 68.75% (55/80) of patients, hormone 
therapy in 78.75% (63/80), immunotherapy in 11.25% (9/80) and 
radiotherapy in 88.75% (71/80). Early breast cancer (Stage I, II) was 
found in 48 patients (60%), advanced breast cancer (stage III, IV) in 32 
patients (40%). Clinical and pathological characteristics of patients are 
shown in Table 4. 
At the circumferential measurements, 37.5 % (30/80) of patients 
had a clinically manifested lymphedema (L > 2cm). Eighteen patients 
(22.5%) with not measured lymphedema, reported subjective 
symptoms (heaviness and swelling) of lymphedema and were 
considered eligible for lymphoscintigraphy. Only 7/18 accepted to 
undergo lymphoscintigraphy and 6 of them showed 
lymphoscintigraphic features of lymphedema. Thus, the overall 
prevalence of lymphedema was 45% (CI 95% 0.3385; 0.5653). 
Specifically, 36 patients (45%) were classified as lymphedema patients 
(cases) of which 37.5% (30/80) showed clinical lymphedema and 7.5% 
(6/80) had a sub-clinical lymphedema. Forty-four (55%) patients had no 
diagnosis of lymphedema and were considered as non-cases. Table 5 
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shows number and percentage of lymphedema and no-lymphedema 
patients recognized in the study population. 
Of the 36 lymphedema patients, 16.7% had stage 0 
lymphedema, 25% had stage I lymphedema, 52.8% had stage II 
lymphedema and 5.5 % had stage III lymphedema. According to the 
lymphedema severity system classification of the ILS, 63.9% (23/36) of 
patients had mild lymphedema, 30.6% (11/36) had moderate 
lymphedema and 5.5% (2/36) had severe lymphedema.  
Univariate analysis showed significant association between the 
occurrence of lymphedema and the following variables: BMI ≥ 30 
Kg/m2 (OR = 2.96, p = 0.035), mastectomy (OR = 4.32, p = 0.021), 
number of excised lymph nodes ≥ 20 (OR= 2.96, p = 0.035) and 
advanced TNM stages of breast cancer (OR = 2.63, p = 0.042). Smoke 
was found to be a protective factor for development of lymphedema  
(OR = 0.18, p = 0.031). Only 1 patient had familiarity for lymphedema 
thus this variable was excluded from statistical analysis. The marginal 
effects of each variable on lymphedema occurrence are shown in 
Tables 6 and 7. 
Multivariate-adjusted analysis showed that a number of excised 
lymph nodes ≥ 20  (OR = 1.09, p = 0.044 ) and mastectomy (OR = 
3.93, p = 0.047) were positively associated with lymphedema. Table 8 
shows the selected logistic regression model. 
 
3.2. Phase II: prospective study 
A total of six lymphedema patients accepted to underwent 
lymphedema surgical treatment according to the inclusion and 
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exclusion criteria established in this phase. Of these, three showed 
early II stage lymphedema and the remaining 3 showed late II stage 
lymphedema. At the physical examination and ICG lymphography, 
patients with early II stage lymphedema had pitting edema and active 
lymphatic channels respectively, thus they underwent lymphatico-
venular anastomosis (LVA group). Patients with late II stage of 
lymphedema had non-pitting edema and non-functioning lymphatic 
channels, thus they were considered for circumferential liposuction (CL 
group). 
In LVA group, the mean percentage of postoperative reduction of 
volume excess between the threated limb and the contralateral control 
side was of 53.3% (range: 51 to 55%) at a follow period of 12 months. 
The mean postoperative value of reduction of the maximum 
preoperative circumferences difference between the threated limb and 
the contralateral control side was 1.5 cm (range: 1.2 to 1.7 cm). In the 
CL group, the mean percentage of postoperative reduction of volume 
excess between the threated limb and the contralateral control side 
was of  88.7% (range: 87 to 90%)  at a follow period of 12 months. The 
mean postoperative value of reduction of the maximum preoperative 
circumferences difference between the threated limb and the 
contralateral control side was 3.7 cm (range: 3.5 to 4 cm). In the two 
groups, none of patients showed postoperative complications. 
Lymphedema patients’ characteristics, surgical treatment details and 
postoperative results are shown in table 9. 
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CHAPTER 4 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
esults from this study demonstrate that the overall 
prevalence of upper limb lymphedema among breast 
cancer survivors is 45% (36/80) 3 years after breast cancer 
treatment. This study showed also a pyramidal arrangement of 
lymphedema presentation. Specifically, 63.9% (23/36) of women had 
early stages of lymphedema (0 to early II ISL stages) with a mild 
severity, 30.6% (11/36) of patients were classified to have late in stage 
II lymphedema with a moderate severity and 5.5% (2/36) of patients 
had a severe stage III lymphedema.  
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The prevalence of lymphedema found in this study is higher 
than the prevalence rates between 9% and 40% reported by other 
studies. 26,40-42  
The explanations why our results disagree with those of other 
studies may be as follows. 
First, prevalence of lymphedema is lower when relies only on clinical 
criteria and increases if multiple diagnostic techniques are applied. 
Many studies may underestimate the real prevalence of the disease 
because the estimation is achieved by using only one diagnostic 
modality.7,26,43-46 In our study, circumferential tape measurements and 
lymphoscintigraphy in patients with self-reported symptoms were used. 
This standardized protocol allows to diagnose lymphedema even in a 
subclinical phase, revealing the submerged portion of the “lymphedema 
iceberg”. 
Second, several studies report that there is an increase in the 
prevalence of lymphedema by the lengthening of the surgical follow-up. 
The risk of developing lymphedema increases persistently until 20 
years after surgery, although most cases occurred within 3 years. Thus, 
studies reporting the prevalence of lymphedema with less than 3 years 
of follow-up would underestimate the true prevalence.7,28,47-48 We 
studied our patients at 3 years, supporting the acquisition of the long-
term prevalence of lymphedema.  
Third, the lack of pre- or immediately post-operative 
measurements could lead to an overestimation (or underestimation) of 
the prevalence of the disease, because the assumption of a 
preoperative equivalence between the healthy and the affected limb in 
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order to perform a comparative assessment at the follow-up could not 
be true due to pre-existing muscular hypertrophy.49 
However, if we consider the prevalence of clinical lymphedema 
(37.5%) revealed in this study, the resulting value can be comparable 
to that of other studies that evaluated the prevalence of the disease in 
patients with similar characteristics (ALND, TNM stage I-III) at a similar 
follow-up time and with similar diagnostic techniques and criteria (L > 
2cm).26,50-52 
Our study showed also that BMI, mastectomy, total number of 
excised lymph nodes and TNM stage are important risk factors in order 
to predict the onset of lymphedema.  
Many studies have described the association between BMI and 
lymphedema.26,48,53-57 This study demonstrated that a BMI ≥ 30 kg/m2 
increases the odds of lymphedema by approximately three times (OR = 
2.96). More than one hypothesis has been introduced to explain the 
association between obesity and lymphedema. Foldi et al. believe that 
obesity acts in synergy with lymphedema, boosting up his negative 
effects. In addition, a high body weight is linked with a reduced 
diaphragmatic excursion, that impairs the mechanism of lymphatic 
suction allowed by negative intrathoracic pressure.58 According to 
Shahpar et al. obesity, especially in advanced age, could worsen the 
severity of lymphedema because it is associated with decreased 
mobility, reduced levels of physical activity and failure of the muscular 
pump.50 
As described in literature, type of breast surgery is considered 
as an important predictive factor for development of lymphedema.50,54-
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55,59-61 Hayes et al. found that the risk of lymphedema is six fold higher 
in patients who underwent a more extensive surgery.28 A possible 
explanation is that an aggressive breast surgery could be responsible 
of a greater damage to lymph system compared to the effect of a more 
conservative surgery.62 The present study further supports these 
findings. Specifically, both univariate (OR = 4.32) and multivariate (OR 
= 3.93) analysis showed an increased probability to develop 
lymphedema in patients that underwent mastectomy compared to 
those that received breast conservative surgical treatment.  
It is generally accepted that more extensive axillary lymph 
nodes dissection (number of removed lymph nodes) results in more 
extensive disruption of lymphatic vessels and, consequently, is 
associated with an increased risk of lymphedema.26,47,50,54-56,63-66 
Axillary lymph node dissection seems to decrease lymphatic drainage 
from the upper limb producing an accumulation of protein-rich fluid into 
the interstitial space. A large number of removed lymph nodes 
increases the risk of postoperative sequelae like seroma that could 
lead to tissue fibrosis and necrosis. In addition, seroma evacuation 
triples the probability to develop lymphedema.67 In this study, a number 
of removed lymph nodes greater than 20 was associated to a 
significantly higher risk of swelling (OR = 2.96). Statistical analysis 
revealed that the odds of lymphedema increased by 9% for each 
additional lymph node removed (OR = 1.09).  
The majority of studies didn’t find any significant association 
between TNM pathological stage of breast cancer and BCRL. Only few 
works reported that an advanced stage of breast cancer is positively 
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related with the onset of lymphedema.25-27 The present study showed 
that an advanced TNM stage is associated with an almost threefold 
increase of the probability of lymphedema (OR = 2.63). This is maybe 
due to metastatic involvement of axillary lymph nodes, that is common 
in advanced stages of disease and could lead to lymphostasis and 
lymph accumulation in the interstitium.68 
Radiation therapy, especially if involves the armpit, could cause 
lymphedema or worsen a pre-existing disease. It could cause tissue 
fibrosis, vasoconstriction of lymph vessels, sclerosis of lymphatic 
vessel walls, resulting in an impaired drainage of the axilla.25-27,50,63,66 
Despite previously researches reported the radiation therapy as a 
predictive factor for lymphedema53,56,61,64-66,69-70, this study didn’t show 
any significant association between radiotherapy and BCRL. As 
described by Hayes et al. it could be related to recent improvements in 
radiation techniques.28 However, it should be emphasized that almost 
the totality of patients enrolled in the present study (71/80) received 
radiation therapy and the majority of them (64/80) underwent BCS as a 
part of the tumorectomy/quadrantectomy, axillary lymphadenectomy 
and radiotheraphy (TART/QUART) protocol. For these reasons, our 
probabilistic sample could be too much homogeneous and then 
inadequate to show the effect of radiation therapy as a risk factor for 
lymphedema. In fact, in the population studied the isolated contribution 
of radiotherapy on lymphedema could be masked by its frequent 
association with quadrantectomy, that is associated with a lower risk of 
lymphedema in comparison with mastectomy. 
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Surprisingly, this study showed that smoking is a protective 
factor against lymphedema (OR = 0.18). Such a striking association is 
supported in literature by only one study referred by Bedi et al.71 
Nicotine, one of the main components of tobacco smoke, is a potent 
vasoconstrictor: it reduces blood flow, inhibits endothelium-dependent 
vasodilation and impairs responses to vasoactive substances.72-74 For 
these reasons smoking reduces the rate of capillary filtration into the 
interstitium and so it could diminish the accumulation of lymph fluid in 
the third space. Angiogenesis is another factor involved in the 
determinism of lymphedema. Smoking inhibits the production of HIF-1 
and VEGF-A: this means that it blocks hypoxia-induced angiogenesis 
leading to minor lymphatic leakage into the interstitial space.71,75 
Currently, once BCRL develops, it is considered as a chronic 
disease that cannot be cured; it can only be managed, with the aims of 
reducing limb size, preventing progression and complications, and 
improving limb function and quality of life. Different therapeutics 
strategies are available in literature ranging from conservative therapy, 
pharmacotherapy, and surgery. 76-77 
Conservative therapy is the primary method currently used to 
treat lymphedema. It includes manual lymph drainage, pneumatic 
pumps, exercise, non-elastic wrapping, use of compression garments, 
and skin care. Treatment effects for conservative therapy are reported 
to be in the range of 8% to 66%. However, a lack of accuracy in studies 
design (absence of case-control groups, small sample size, variability 
in follow-up measures) severely influence the strength of these 
findings.76-78  
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The use of medications such as benzopyrones and selenium 
compounds to manage secondary lymphedema is currently 
emphasized. However, systematic reviews of the literature evaluating 
the effectiveness of these compounds report that there is no evidence 
in support of their use.76-80 
Surgery for lymphedema is typically recommended when 
conservative treatment is unsuccessful or impractical. Different 
techniques ranging from reconstructive to ablative procedures are 
described in literature for the management of BCRL. However, there is 
still a wide variation in reported outcomes probably due to a lack of 
standardization in the indications and post-operative follow-up 
measures.5-6,76-78 As described by Masià et al., excellent results in 
terms of reduction of excess of limb volume, improvements in limb 
function and quality of life could be achieved with the use of 
lymphatico-venular anastomosis and liposuction if a meticulous 
preoperative assessment and a customized surgical approach are 
performed in selected BCRL patients.30 Our results, even if obtained in 
a small series (6 patients) and for a short follow up period (12 months), 
further support these findings. Specifically, lymphatico-venular 
anastomosis technique applied in lymphedema patients with pitting 
edema and functioning lymphatic vessels allowed an average reduction 
of limb volume excess of 53.3%; circumferential liposuction technique 
allowed to obtain an average limb volume reduction of 88.7% in 
patients with no-pitting edema and non-functioning lymphatic vessels. 
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CHAPTER 5 
 
 
 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
esults from this study highlight that Breast Cancer-Related 
Lymphedema is an emergent complication affecting breast 
cancer survivors with a long-term prevalence of 45%. This 
means that about one in two women will develop lymphedema after 
breast cancer treatment. Specifically, obese women in advanced breast 
cancer stages, treated with mastectomy and extensive axillary 
lymphadenectomy (total number of removed lymph nodes ≥ 20) seem 
to be at major risk. These patients should be referred to educational 
programs and monitoring service with the aim to prevent or recognize 
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the early onset of lymphedema. Once developed, lymphedema is 
difficult to manage. If it is not promptly diagnosed and treated in early 
period, treatment may be unsuccessful. Thus, early detection of 
lymphedema is mandatory to allow the application of early conservative 
therapy that represents the primary strategy of care. However, even 
though prevention programs and conservative treatments should fail, 
surgical treatment could promise satisfactory results enabling to 
improve the quality of life of BCRL patients. 
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CHAPTER 6 
 
 
 
Tables and Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1. Patients’ recruitment flow chart 
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Figure 2. Upper limbs circumferential measurement with flexible tape 
	  
Figure 3. Geometrical model to estimate limb volume. 
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Figure 4. Anterior projection (ANT) of lymphoscintigraphic image taken 
at  120 minutes after injection of the radiotracer in the second 
interdigital web space of both hands). This patient shows absent 
visualization of supraclavicular or infra-clavicular lymph nodes (green 
arrow) and dermal back flow (red arrow) on the right (R) upper limb.  
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Figure 5. Diagnostic algorithm of upper limb lymphedema. 
	  
Lymphedema	  Staging	  System	  of	  the	  International	  Society	  of	  Lymphology	  (ISL)	  
Stage	  0	   Latent	  or	  subclinical	  condition	  where	  swelling	  is	  not	  yet	  evident	  
despite	  impaired	  lymph	  transport	  that	  can	  be	  assessed	  with	  
lymphoscintigraphy	  (patients	  who	  underwent	  mastectomy	  and	  
whose	  arms	  are	  equal	  in	  volume	  and	  consistency).	  It	  may	  exist	  
months	  or	  years	  before	  overt	  edema	  occurs.	   	  
Stage	  I	   Early	  accumulation	  of	  fluid	  relatively	  high	  in	  protein	  content	  
which	  subsides	  with	  limb	  elevation.	  Pitting	  may	  occur.	  
Stage	  II	  
(early)	  
Limb	  elevation	  alone	  rarely	  reduces	  tissue	  swelling	  and	  pitting	  is	  
manifest.	  
Stage	  II	  
(late)	  
Limb	  elevation	  does	  not	  reduce	  tissue	  swelling.	  The	  limb	  may	  or	  
may	  not	  pit	  as	  excess	  fat	  and	  fibrosis	  supervenes.	  
Stage	  III	   Lymphostatic	  elephantiasis	  with	  disappearance	  of	  bony	  
landmarks,	  where	  pitting	  can	  be	  absent	  and	  trophic	  skin	  changes	  
such	  as	  acanthosis,	  further	  deposition	  of	  fat	  and	  fibrosis,	  and	  
warty	  overgrowths	  have	  developed.	   	   	  
Table 1. Lymphedema staging system of the International Society of 
Lymphology (ISL). 
	  
Lymphedema	  Severity	  System	  of	  the	  International	  Society	  of	  Lymphology	  (ISL)	  
Mild	   <20%	  increase	  in	  limb	  volume	  (in	  comparison	  with	  the	  
contralateral	  limb)	  
Moderate	   20-­‐40%	  increase	  in	  limb	  volume	  
Severe	   >	  40%	  increase	  in	  limb	  volume	  
Table 2. Lymphedema Severity System of the International Society of 
Lymphology (ISL) 
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Figure 6. Lymphatico-venular anastomosis technique: (A) 
Preoperatively, 0,2 ml of ICG were injected in the second web-space of 
the affected hand. PDE system confirmed that ICG was flowing up 
through the lymphatic vessels in the adipose tissue. (B) Then the 
location and paths of active lymphatic channels were traced on the skin 
using a marker pencil. (C) After skin incision, a small vein that lie 
beneath in the superficial fat layer and an adjacent lymphatic vessel 
were exposed and transected  by using an operative microscope. (D) 
An end-to-end (distal stump of the lymphatic vessel with proximal 
stump of the venule) anastomosis was performed with six interrupted 
stitches using nylon 10/0. (E) Patency of anastomosis was tested by 
injecting 0,2 ml of Patent Blue 2 cm distal the skin incision. (F) Skin 
incision was closed with interrupted stitches using nylon 4/0. 
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Figure 7. Circumferential liposuction technique: (A) Under general 
anaesthesia, a tourniquet was place at the proximal part of the affected 
limb. (B) Ten  to fifteen, 3-mm-long incisions  were made 
circumferentially on the entire affected limb until the tourniquet and a 
tumescent saline solution (1 to 2 L) containing low-dose adrenaline and 
lignocaine was injected in the adipose tissue to reduce blood loss. (C-
D)Tourniquet was inflated and power-assisted liposuction was 
performed circumferentially from the wrist to the shoulder using 15 and 
25 cm long cannulas with diameter of 3 and 4 mm. (E)	  When the entire 
arm was treated, (F) a multilayer bandage was applied in order to 
absorb bleeding and reduce edema. 
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Table 3. Demographic, past medical history and lifestyle characteristics 
of patients enrolled. 
Variable Mean (Range, ±SD) No. (%)
Age at the time of surgery (years) 58.1625 (37 - 83, ±9.6291)
≥60 29 (36.25)
<60 51 (63.75)
BMI 28.0888 (18.3 - 46.6, ±5.8372)
≥30 29 (36.25)
<30 51 (63.75)
Dominant side
Right 80 (100.00)
Left 0 (0.00)
Smoking 1.6750 (0 - 20, ±4.5695)
Yes 13 (16.25)
No 67 (83.75)
Alcohol
Yes 27 (33.75)
No 53 (66.25)
Coffee 2.0127 (0 - 5, ±1.2877)
Yes 71 (88.75)
No 9 (11.25)
Comorbidities
Yes 65 (81.25)
No 15 (18.75)
Familiarity
Yes 1 (1.25)
No 79 (98.75)
Past surgery
Yes 14 (17.50)
No 66 (82.50)
History of upper limb trauma
Yes 9 (11.25)
No 71 (88.75)
Diabetes mellitus
Yes 10 (12.50)
No 70 (87.50)
Thyroid disease
Yes 15 (18.75)
No 65 (81.25)
Venous system disease
Yes 16 (20.00)
No 64 (80.00)
Hypertension
Yes 28 (35.00)
No 52 (65.00)
Cardiovascular disease
Yes 8 (10.00)
No 72 (90.00)
Osteoarticular disease
Yes 21 (26.25)
No 59 (73.75)
Dyslipidemia
Yes 6 (7.50)
No 74 (92.50)
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Table 4. Clinical and pathological characteristics of patients enrolled. 
 
 
Variable Mean (Range, ±SD) No. (%)
Histologic type
Ductal 69 (86.25)
Lobular 11 (13.75)
TNM Stage
Early 48 (60.00)
1A 6 (7.50)
1B 2 (2.50)
2A 27 (33.75)
2B 13 (16.25)
Advanced 32 (40.00)
3A 18 (22.50)
3B 3 (3.75)
3C 6 (7.50)
4 5 (6.25)
Affected side
Right 46 (57.50)
Left 34 (42.50)
Type of breast surgery
Mastectomy 15 (18.75)
Quadrantectomy 65 (81.25)
Surgery in the dominant side
Yes 46 (57.50)
No 34 (42.50)
No. of excised lymph nodes 17.2727 (2 - 41, ±6.1307)
≥20 29 (36.25)
1-19 51 (63.75)
No. of positive lymph nodes 4.000 (0 - 24, ±5.4121)
≥4 30 (37.50)
1-3 50 (62.50)
Radiation therapy
Yes 71 (88.75)
No 9 (11.25)
Chemotherapy
Yes 55 (68.75)
No 25 (31.25)
Hormone therapy
Yes 63 (78.75)
No 17 (21.25)
Immunotherapy
Yes 9 (11.25)
No 71 (88.75)
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Table 5. Prevalence of lymphedema: lymphedema and non-
lymphedema patients in the study population. 
Table 6. Demographic and past history characteristics of patients. 
Univariate analysis: contingency tables, odds ratios, 95% confidence 
intervals and p-values for discrete variables. 
2010 2011 2012 2010-­‐2012
No.	  (%) No.	  (%) No.	  (%) No.	  (%)
TOTAL 38	  (100.00) 12	  (100.00) 30	  (100.00) 80	  (100.00)
ABSENT 18	  (47.37) 6	  (50.00) 20	  (66.67) 44	  (55.00)
SUBCLINICAL* 2	  (5.26) 2	  (16.67) 2	  (6.67) 6	  (7.50)
CLINICAL** 18	  (47.37) 4	  (33.33) 8	  (26.66) 30	  (37.50)
CLINICAL	  +	  SUBCLINICAL 20	  (52.63) 6	  (50.00) 10	  (33.33) 36	  (45.00)
NOTES:	  *Diagnosed	  by	  lymphoscintigraphy	  **Diagnosed	  by	  circumferential	  tape	  measurement
DIAGNOSIS	  OF	  LYMPHEDEMA
YEAR
Variable No. Cases No. Non-cases OR (95% CI) P -value
Age at the time of surgery (years)
≥60 13 16 0.9893 (0.3565 - 2.7199) 1
<60 23 28
BMI
≥30 18 11 2.9568 (1.0582 - 8.6318) 0.0346*
<30 18 33
Smoking
Yes 2 11 0.1799 (0.0180 - 0.9178) 0.0306*
No 34 33
Alcohol
Yes 10 17 0.6146 (0.2094 - 1.7340) 0.3490
No 26 27
Coffee
Yes 30 41 0.3705 (0.0555 - 1.9015) 0.2861
No 6 3
Comorbidities
Yes 31 34 1.8102 (0.4962 - 7.5295) 0.3942
No 5 10
Past surgery
Yes 9 5 2.5685 (0.6830 - 10.8958) 0.1432
No 27 39
History of upper limb trauma
Yes 3 6 0.5796 (0.0870 - 2.9730) 0.5035
No 33 38
Diabetes mellitus
Yes 4 6 0.7940 (0.1510 - 3.6900) 1
No 32 38
Thyroid diseases
Yes 7 8 1.0851 (0.2964 - 3.8888) 1
No 29 36
Venous system disease
Yes 9 7 1.7493 (0.5071 - 6.2896) 0.4023
No 27 37
Hypertension
Yes 15 13 1.6918 (0.6101 - 4.7686) 0.3466
No 21 31
Cardiovascular disease
Yes 4 4 1.2465 (0.2143 - 7.2527) 1
No 32 40
Osteoarticular disease
Yes 9 12 0.8902 (0.2840 - 2.7115) 1
No 27 32
Dyslipidemia
Yes 2 4 0.5920 (0.0506 - 4.4252) 0.6853
No 34 40
NOTES: *p < 0.05
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Table 7. Clinical and pathological characteristics of patients. 
Contingency tables, odds ratios, 95% confidence intervals and p-values 
for discrete variables. 
 
Table 8. Multivariate analysis of significant risk factors associated with 
lymphedema. 
 
Variable No. Cases No. Non-cases OR (95% CI) P -value
Histologic type
Ductal 30 39 0.6446 (0.1410 - 2.8078) 0.5306
Lobular 6 5
TNM Stage
Advanced 19 13 2.6312 (0.9657 - 7.4196) 0.0416*
Early 17 31
Type of breast surgery
Mastectomy 11 4 4.3172 (1.1237 - 20.6694) 0.0207*
Quadrantectomy 25 40
Surgery in the dominant side
Yes 21 25 1.0632 (0.3984 - 2.8570) 1
No 15 19
No. of excised lymph nodes
≥20 18 11 2.9568 (1.0582 - 8.6318) 0.0346*
1 - 19 18 33
No. of positive lymph nodes
≥4 16 14 1.7026 (0.6239 - 4.7208) 0.2579
1 - 3 20 30
Radiation therapy
Yes 29 42 0.2012 (0.0191 - 1.1575) 0.0708
No 7 2
Chemotherapy
Yes 27 28 1.7028 (0.5882 - 5.1790) 0.3362
No 9 16
Hormone therapy
Yes 28 35 0.9012 (0.2685 - 3.0701) 1
No 8 9
Immunotherapy
Yes 3 6 0.5796 (0.0870 - 2.9730) 0.5035
No 33 38
NOTES: *p < 0.05
Variable β SE (β) P -value OR
BMI 0.9399 0.5351 0.0790 2.5597
Smoking -1.5162 0.8692 0.0811 0.2196
TNM Stage 0.5458 0.5383 0.3107 1.7259
Type of breast surgery 1.3686 0.6876 0.0465* 3.9299
No. of excised lymph nodes 0.0888 0.0441 0.0442* 1.0929
Intercept -2.3750 0.8594 0.0057*
-2Log Likelihood 88.7866
AIC 100.7866
NOTES: *p < 0.05
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